New attack treatment tested for rare autoimmune nerve disease
NCT ID NCT07184840
Summary
This study is testing if the drug eculizumab can help people with neuromyelitis optica spectrum disorder (NMOSD) during a sudden, severe attack. The drug is already approved to prevent these attacks, but researchers want to see if it can also stop damage and improve symptoms quickly when an attack happens. They will enroll 110 adults who are having an acute attack to measure improvements in vision, movement, and other functions over 28 days.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University General Hospital
RECRUITINGTianjin, Tianjin Municipality, 300052, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.